Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

BACKGROUND: Although docetaxel-based chemohormonal therapy (CHT) is one of the standard treatments for castration-resistant prostate cancer (CRPC), pertinent biomarkers and precise mechanisms involved in the resistance for CHT for CRPC remain unknown. We investigated the relationship between chemoho...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuda, Yoshinori, Narita, Shintaro, Nara, Taketoshi, Mingguo, Huang, Sato, Hiromi, Koizumi, Atsushi, Kanda, Sohei, Numakura, Kazuyuki, Saito, Mitsuru, Inoue, Takamitsu, Hiroshima, Yuko, Nanjo, Hiroshi, Satoh, Shigeru, Tsuchiya, Norihiko, Habuchi, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333261/
https://www.ncbi.nlm.nih.gov/pubmed/32293349
http://dx.doi.org/10.1186/s12885-020-06844-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333261/
https://www.ncbi.nlm.nih.gov/pubmed/32293349
http://dx.doi.org/10.1186/s12885-020-06844-y

Ejemplares similares